{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:28:58Z","timestamp":1793320138113,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":752,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding treatment for patients with SSc-ILD are primarily consensus based.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An international expert guideline committee composed of 24 individuals with expertise in rheumatology, SSc, pulmonology, ILD, or methodology, and with personal experience with SSc-ILD, discussed systematic reviews of the published evidence assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Predetermined conflict-of-interest management strategies were applied, and recommendations were made for or against specific treatment interventions exclusively by the nonconflicted panelists. The confidence in effect estimates, importance of outcomes studied, balance of desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications for health equity were all considered in making the recommendations. This was in accordance with the American Thoracic Society guideline development process, which is in compliance with the Institute of Medicine standards for trustworthy guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For treatment of patients with SSc-ILD, the committee: 1) recommends the use of mycophenolate; 2) recommends further research into the safety and efficacy of (a) pirfenidone and (b) the combination of pirfenidone plus mycophenolate; and 3) suggests the use of (a) cyclophosphamide, (b) rituximab, (c) tocilizumab, (d) nintedanib, and (e) the combination of nintedanib plus mycophenolate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The recommendations herein provide an evidence-based clinical practice guideline for the treatment of patients with SSc-ILD and are intended to serve as the basis for informed and shared decision making by clinicians and patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202306-1113st","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T10:00:16Z","timestamp":1695981616000},"page":"137-152","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":175,"title":["Treatment of Systemic Sclerosis\u2013associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline"],"prefix":"10.1093","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-6643","authenticated-orcid":false,"given":"Ganesh","family":"Raghu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-6808","authenticated-orcid":false,"given":"Sydney B.","family":"Montesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-3278","authenticated-orcid":false,"given":"Richard M.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1995-7828","authenticated-orcid":false,"given":"Tanzib","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-9587","authenticated-orcid":false,"given":"Madalina","family":"Macrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-8128","authenticated-orcid":false,"given":"Derrick","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-4191","authenticated-orcid":false,"given":"Hayley","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-9610","authenticated-orcid":false,"given":"Ayodeji","family":"Adegunsoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-9966","authenticated-orcid":false,"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0072-6939","authenticated-orcid":false,"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3481-8591","authenticated-orcid":false,"given":"Gregory C.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-0725","authenticated-orcid":false,"given":"Kristin B.","family":"Highland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0527-576X","authenticated-orcid":false,"given":"Robert J.","family":"Kaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-1467","authenticated-orcid":false,"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6513-8893","authenticated-orcid":false,"given":"Mary Beth","family":"Scholand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-0133","authenticated-orcid":false,"given":"Virginia","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey C.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-6569","authenticated-orcid":false,"given":"Elizabeth R.","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M.","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Burlile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-809X","authenticated-orcid":false,"given":"Karen A.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4404-3833","authenticated-orcid":false,"given":"Shandra L.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6822","authenticated-orcid":false,"given":"Marya","family":"Ghazipura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"2026012204205777700_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma): subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2026012204205777700_bib2","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026012204205777700_bib3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204205777700_bib4","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012204205777700_bib5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026012204205777700_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026012204205777700_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026012204205777700_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/BOR.0000000000000795","article-title":"Treatment for systemic sclerosis-associated interstitial lung disease","volume":"33","author":"Roofeh","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2026012204205777700_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026012204205777700_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"key":"2026012204205777700_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026012204205777700_bib12","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"2026012204205777700_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: a systematic review","volume":"32","author":"Trang","year":"2012","journal-title":"Rheumatol Int"},{"key":"2026012204205777700_bib14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2026012204205777700_bib15","doi-asserted-by":"crossref","DOI":"10.17226\/13058","volume-title":"Clinical practice guidelines we can trust","author":"Graham","year":"2011"},{"key":"2026012204205777700_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/rccm.200602-197ST","article-title":"An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations","volume":"174","author":"Sch\u00fcnemann","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204205777700_bib17","doi-asserted-by":"crossref","article-title":"Cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","author":"Barnes","DOI":"10.1513\/AnnalsATS.202301-053OC"},{"key":"2026012204205777700_bib18","article-title":"Mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","author":"Herman","year":"2023"},{"key":"2026012204205777700_bib19","doi-asserted-by":"crossref","article-title":"Rituximab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","author":"Macrea","DOI":"10.1513\/AnnalsATS.202301-055OC"},{"key":"2026012204205777700_bib20","doi-asserted-by":"crossref","article-title":"Tocilizumab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","author":"Ghazipura","DOI":"10.1513\/AnnalsATS.202301-056OC"},{"key":"2026012204205777700_bib21","doi-asserted-by":"crossref","article-title":"Nintedanib therapy alone and combined with mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: systematic reviews and meta-analysis","author":"Herman","DOI":"10.1513\/AnnalsATS.202301-081OC"},{"key":"2026012204205777700_bib22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2004.033076","article-title":"Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations","volume":"64","author":"Kowal-Bielecka","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2026012204205777700_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide toxicity. Characterising and avoiding the problem","volume":"42","author":"Fraiser","year":"1991","journal-title":"Drugs"},{"key":"2026012204205777700_bib24","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026012204205777700_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","article-title":"Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis","volume":"18","author":"Shenoy","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026012204205777700_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"key":"2026012204205777700_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjmed.2010.12.009","article-title":"Adverse events during the Scleroderma Lung Study","volume":"124","author":"Furst","year":"2011","journal-title":"Am J Med"},{"key":"2026012204205777700_bib28","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.chest.2021.11.033","article-title":"Early radiographic progression of scleroderma: lung disease predicts long-term mortality","volume":"161","author":"Volkmann","year":"2022","journal-title":"Chest"},{"key":"2026012204205777700_bib29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204205777700_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"2026012204205777700_bib31","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1513\/AnnalsATS.201802-079OC","article-title":"Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II","volume":"15","author":"Goldin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2026012204205777700_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026012204205777700_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026012204205777700_bib34","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026012204205777700_bib35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation\u2019s direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026012204205777700_bib36","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026012204205777700_bib37","doi-asserted-by":"crossref","first-page":"e000384","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"2026012204205777700_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2026012204205777700_bib39","doi-asserted-by":"crossref","first-page":"E489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026012204205777700_bib40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012204205777700_bib41","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"2026012204205777700_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026012204205777700_bib43","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","article-title":"Long-term safety and efficacy of tocilizumab in early systemic sclerosis-interstitial lung disease: open-label extension of a phase 3 randomized controlled trial","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204205777700_bib44","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026012204205777700_bib45","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204205777700_bib46","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012204205777700_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.41576","article-title":"Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Maher","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026012204205777700_bib48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012204205777700_bib49","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204205777700_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012204205777700_bib51","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026012204205777700_bib52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026012204205777700_bib53","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"issue":"suppl 9","key":"2026012204205777700_bib54","first-page":"0520","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/2\/137\/66431235\/ajrccm_209_2_137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/209\/2\/137\/66431235\/ajrccm_209_2_137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:22:49Z","timestamp":1769073769000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/209\/2\/137\/8427551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,1,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202306-1113st","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}